Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance

Gauttier, Vanessa; Pengam, Sabrina; Durand, Justine; Biteau, Kévin; Mary, Caroline; Morello, Aurore; Néel, Mélanie; Porto, Georgia; Teppaz, Géraldine; Thépenier, Virginie; Danger, Richard; Vince, Nicolas; Wilhelm, Emmanuelle; Girault, Isabelle; Abès, Riad; Ruiz, Catherine; Trilleaud, Charlène; L. M. Ralph, Kerry; Sergio Trombetta, E.; Garcia, Alexandra; Vignard, Virginie; Martinet, Bernard; Glémain, Alexandre; Bruneau, Sarah; Haspot, Fabienne; Dehmani, Safa; Duplouye, Pierre; Miyasaka, Masayuki; Labarrière, Nathalie; Laplaud, David; Le Bas‐Bernardet, Stéphanie; Blanquart, Christophe; Catros, Véronique; Gouraud, Pierre-Antoine; Archambeaud, Isabelle; Aublé, Hélène; Métairie, Sylvie; Mosnier, Jean‐François; Costantini, D; Blancho, Gilles; Conchon, Sophie; Vanhove, Bernard; Poirier, Nicolas

doi:10.1172/jci135528

Public

Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance

Published in Journal of Clinical Investigation • Oct 18, 2020

Authors:

Vanessa Gauttier

Sabrina Pengam

Justine Durand

Abstract

T cell exclusion causes resistance to cancer immunotherapies via immune checkpoint blockade (ICB). Myeloid cells contribute to resistance by expressing signal regulatory protein-α (SIRPα), an inhibitory membrane receptor that interacts with ubiquitous receptor CD47 to control macrophage phagocytosis...

Subject

CD47

Tumor microenvironment

Cancer research

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!